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http://www.biomedcentral.com/1471-2261/14/138RESEARCH ARTICLE Open AccessAn intervention to reassure patients about test
results in rapid access chest pain clinic: a pilot
randomised controlled trial
Kathryn Hicks1*, Kim Cocks1, Belen Corbacho Martin1, Peter Elton2, Anita MacNab3, Wendy Colecliffe3
and Gill Furze4Abstract
Background: Most people referred to rapid access chest pain clinics have non-cardiac chest pain, and in those
diagnosed with stable coronary heart disease, guidance recommends that first-line treatment is usually medication
rather than revascularisation. Consequently, many patients are not reassured they have the correct diagnosis or
treatment. A previous trial reported that, in people with non-cardiac chest pain, a brief discussion with a health
psychologist before the tests about the meaning of potential results led to people being significantly more
reassured. The aim of this pilot was to test study procedures and inform sample size for a future multi-centre trial
and to gain initial estimates of effectiveness of the discussion intervention.
Methods: This was a two-arm pilot randomised controlled trial in outpatient rapid access chest pain clinic in 120
people undergoing investigation for new onset, non-urgent chest pain. Eligible participants were randomised to
receive either: a discussion about the meaning and implication of test results, delivered by a nurse before tests in
clinic, plus a pre-test pamphlet covering the same information (Discussion arm) or the pre-test pamphlet alone
(Pamphlet arm). Main outcome measures were recruitment rate and feasibility for a future multi-centre trial, with
an estimate of reassurance in the groups at month 1 and 6 using a 5-item patient-reported scale.
Results: Two hundred and seventy people attended rapid access chest pain clinic during recruitment and
120/270 participants (44%) were randomised, 60 to each arm. There was no evidence of a difference between
the Discussion and Pamphlet arms in the mean reassurance score at month 1 (34.2 vs 33.7) or at month 6
(35.3 vs 35.9). Patient-reported chest pain and use of heart medications were also similar between the two arms.
Conclusions: A larger trial of the discussion intervention in the UK would not be warranted. Patients reported
high levels of reassurance which were similar in patients receiving the discussion with a nurse and in those
receiving a pamphlet alone.
Trial registration: Current Controlled Trials ISRCTN60618114 (assigned 27.05.2011).
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Chest pain is a common reason why people access
health services, with over 400,000 people per year being
referred to rapid access chest pain clinics (RACPCs) in
England [1]. RACPCs were set up in the UK to assess
patients with new onset chest pain within two weeks of
reporting symptoms to their general practitioner (GP)
[2]. In clinic patients undergo basic clinical assessment
and investigation in order to confirm or rule out coronary
heart disease (CHD) as a cause of their chest pain.
Although the main focus in RACPC is detection of new
angina, the majority (up to 80%) of patients will be cate-
gorised as having non-cardiac chest pain (NCCP) [3-5].
However, as studies in people undergoing outpatient tests
for heart disease have shown, many with a negative (nor-
mal) result are not reassured that their chest pain is non-
cardiac in origin [6,7], and continue to report chest pain
in the following months and use NHS services [3,8]. There
are several causes of NCCP, including physical problems
(e.g. gastroesophageal disorders, musculoskeletal causes)
or psychological disorders (such as anxiety, panic attacks,
and depression), and often there is an interaction between
psychological and physical causes [9].
Psychological factors have been targeted for treatment
of NCCP. A recent review of randomised controlled trials
(RCTs) of psychological interventions for symptomatic
management of non-specific chest pain in patients with
normal coronary anatomy showed modest to moderate
success in terms of reduced chest pain frequency, parti-
cularly for those using cognitive behavioural therapy [10].
This success was relatively short term, being largely re-
stricted to the 3 months after the intervention. Brief inter-
ventions, delivered immediately after negative (normal)
findings, have been tested but these have mostly been un-
successful. For example, an RCT of a brief psychological
intervention for people following coronary angiography
who were told they had normal coronary arteries showed
no benefit [11]. The authors concluded that the patients
were “clearly ill prepared for the possibility of negative
findings”.
Petrie et al. (2007) undertook a small RCT in New
Zealand (NZ) to assess whether it was possible to im-
prove people’s preparedness for negative results, and so
increase reassurance [12]. The study compared usual
care with two interventions delivered before tests in chest
pain clinic, as Petrie et al. hypothesised that providing a
pre-test explanation about the meaning of normal test
results would weaken preconceptions about possible ill-
ness, provide context for the results and so increase the
person’s potential for reassurance. The interventions were:
i) a pamphlet giving information about the meaning of
normal results and other possible reasons for chest pain,
and ii) the pamphlet plus a brief pre-test discussion with a
health psychologist re-iterating the same information.People receiving the pre-test discussion were more reas-
sured at one month after the test than patients randomised
to the pamphlet alone or to the usual care arm (results
explained after the test). Only the difference between the
discussion and usual care arms reached statistical signifi-
cance when considering mean reassurance score (from a
5-item patient-reported scale). The proportion of patients
reporting chest pain at one month decreased significantly
from baseline in the discussion group and pamphlet-only
group, but not in the usual care group. It is possible that a
key element in the relative success of the NZ pre-test
interventions was the fact that they were delivered before
the test. Donkin et al. found that, in people with NCCP,
patients’ beliefs before an exercise stress test predicted the
amount of reassurance they felt once they had received
their negative test result [13].
It is not only those who get a negative result in RACPC
that may require reassurance; patients who receive a posi-
tive result (CHD) may also need reassuring. According to
guidance from the National Institute for Health and
Care Effectiveness (NICE), initial treatment for people
diagnosed with stable CHD should be optimal pharma-
cotherapy to control symptoms together with effective
secondary prevention. Interventions such as percutaneous
coronary intervention or coronary artery bypass graft
surgery should be restricted to those in whom optimal
medical treatment fails to reduce symptoms, or if further
testing by non-invasive imaging or by angiography shows
left main stem or severe three-vessel disease [14]. This
pathway needs to be explained well to patients in order to
reassure them that they are receiving the optimal treat-
ment for their condition. For example, it is possible that
patients prescribed medical treatment rather than invasive
revascularisation may feel that they are receiving a second-
best treatment. The converse is also true; people referred
for invasive intervention will need to be reassured that this
level of treatment is appropriate for them. A relationship
between satisfaction with treatment and reports of anxiety,
depression and quality of life has been demonstrated
[15], hence dissatisfaction with treatment may lead to an
increase in health service use.
The NZ study was limited by small sample size and
short duration of follow-up (one month), and it only
included people with NCCP. The clinical pathway for
patients with chest pain differs between NZ and the UK
and the discussion intervention was delivered by a health
psychologist, a profession which is not routinely available
in NHS outpatient clinics.
The aim of this study was to adapt the discussion
intervention for delivery in UK RACPCs and conduct a
2-arm pilot RCT comparing discussion (plus pamphlet)
versus pamphlet alone. The pre-test pamphlet had already
been recommended for use at the study site, as part of the
chest pain pathway. The aim of the pilot trial was to test
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primary outcome measure and the sample size calcu-
lation for a future, multi-centre RCT of effectiveness
and cost-effectiveness. A preliminary investigation into
whether the face-to-face discussion with a nurse may
improve patient reassurance was also made. If a simple
discussion intervention was found to be effective and
cost-effective when delivered by a nurse to people with
both NCCP and with a diagnosis of CHD in UK RACPCs,
then it could be relatively easily incorporated into the
clinical pathway.Methods
Development of the interventions
The NZ discussion intervention and pamphlet were
adapted so that they covered both positive and negative
test results, and the different treatment options. This
was undertaken by an expert reference group with input
from service users and RACPC staff. The pamphlet (A5,
4-page booklet, 664 words; see Additional file 1) outlined:
the three possible results from tests in RACPC that day
(negative/normal (NCCP), positive/abnormal (CHD), or
inconclusive i.e. need to return for more tests); the mean-
ing of negative results with a high risk of developing heart
disease versus low risk; possible reasons for chest pain
in those with a negative result (e.g. muscular, gastro-
esophageal reflux disease); what to do if results are
negative but chest pain continues; and treatment op-
tions for those with a positive result (medication with
review at 3 months or angiogram, possibly indicating
angioplasty or surgery). The brief discussion intervention
(5–15 min), to be delivered by a research nurse rather
than a health psychologist, re-iterated the same informa-
tion, and checked that the patient understood the infor-
mation. A topic guide (463 words) was developed for the
research nurse delivering the intervention. The guide was
not a script to be read verbatim, but outlined the topics to
be covered in the discussion. The research nurse was
trained by the Chief Investigator to deliver the discussion
intervention and to check that the patient understood the
information.Study design and setting
This was a single-centre, two-arm, pilot RCT comparing
a pre-test discussion intervention plus a pre-test pamphlet
(covering the same information) versus the pamphlet
alone in patients attending RACPC with new onset chest
pain. The study was conducted at the University Hospital
of South Manchester (UHSM; Manchester, UK) RACPC.
It was approved by North West 9 Research Ethics Com-
mittee – Greater Manchester West (reference no. 10/
H1014/82) and the R&D Directorate of UHSM NHS
Foundation Trust.Study population and patient consent
Patients were sent information about the trial with their
RACPC appointment letter and asked on arrival at clinic
if they wished to take part. Patients were eligible if they
were: attending RACPC for assessment of new-onset,
non-urgent chest pain; able to read written English; able
to comprehend spoken English; aged 18 years and over
and able and willing to give informed consent. Patients
were excluded if they: had a previously diagnosed car-
diac pathology; had no symptoms of chest pain; were
undertaking the exercise test as part of a pre-surgical
medical examination; were pregnant; were involved in
another research study; had a severe documented psy-
chiatric disorder or had a life-threatening co-morbidity.
Eligible patients gave written informed consent.
Randomisation
Patients were randomised by a research nurse telephon-
ing a remote randomisation service (York Trials Unit
(YTU), University of York, UK). Random permuted blocks
(block sizes of four and six) were used to allocate patients
in a 1:1 ratio.
Blinding
Patients were told that the study was to compare two
different ways of giving information about possible test
results and treatments but not what the two formats
were (pamphlet and discussion), or that one (the pamphlet)
was considered to be the control arm. Staff treating pa-
tients in the RACPC appointment were not informed of
treatment group allocation.
Intervention arms
After randomisation, all patients were given the pre-test
pamphlet by the research nurse and were allowed suffi-
cient time to read it. Patients allocated to the Discussion
arm were then engaged in a brief (5–15 min) discussion
with the research nurse. After receiving the pamphlet
and discussion (Discussion arm), or the pamphlet alone
(Pamphlet arm), patients returned to clinic and under-
went assessment and tests as usual. All patients received
the usual advice and information from staff during
the initial RACPC appointment and any visits for fur-
ther tests.
Assessment in RACPC
Assessment in clinic was led by a senior cardiac specialist
nurse according to UHSM’s protocol. It included an as-
sessment of risk factors, typicality of symptoms (symptom
score 0 to 3), Diamond and Forrester percentage score
[16] and the probability that the patient had a cardiac
cause for the pain (high, medium or low). Patients had
the following tests as indicated: resting electrocardio-
gram, blood pressure measurement, auscultation of heart
Table 1 5-item reassurance questionnaire
1. How worried are you about your health?
0 1 2 3 4 5 6 7 8 9 10
Not at all Extremely worried
2. How much do you believe that there is something seriously wrong
with your heart?
0 1 2 3 4 5 6 7 8 9 10
Not at all Strongly believe
3. How reassured were you by the test?
0 1 2 3 4 5 6 7 8 9 10
Not at all Extremely reassured
4. How much do you believe that you will need further tests to find out
the cause of your illness?
0 1 2 3 4 5 6 7 8 9 10
Not at all Strongly believe
5. How accurate do you think the test was for identifying heart problems?
0 1 2 3 4 5 6 7 8 9 10
Not at all Extremely accurate
The three negatively worded items (1, 2 and 4) were reversed and the five
scores summed, a higher score indicating higher levels of reassurance.
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exercise tolerance test (ETT), dobutamine stress echo-
cardiogram (DSE), exercise echocardiogram, myocardial
perfusion scan (MPS) and magnetic resonance imaging
(MRI). The assessment in RACPC lasted up to four hours
depending on the number of tests conducted.
At the end of the initial appointment patients were
either given a diagnosis (CHD or NCCP) or, if a particu-
lar test (usually DSE) could not be performed on the
day, they were asked to return for further tests. In each
case, test results/diagnosis were explained to the patient
by a clinic nurse, face-to-face, before leaving clinic. Patients
with NCCP were reassured that there was no evidence of
coronary disease and were advised to see their GP within
the next week for reassessment for other causes of the
chest pain. Other possible causes of the chest pain were
suggested if the patient asked, but the nurse emphasised
that they should go to their GP. If patients were at high
risk of developing heart disease, lifestyle-change advice and
leaflets were provided to the patient, and their GP was
informed that aggressive risk factor management was
needed. A CHD diagnosis resulted in the initiation of
appropriate treatment: medication with review after
3 months or referral for an angiogram (possibly followed
by angioplasty or surgery).
Outcome measurements
As this was a pilot study, primary outcomes included
recruitment rate and process, proportion of patients
attending RACPC randomised, and reasons for non-par-
ticipation. The study was powered to give initial estimates
of effectiveness using the patient-reported 5-item reassur-
ance questionnaire used in the NZ study [12] (Table 1).
Outcomes were proportion of patients reassured (as de-
fined by Petrie et al.) and reassurance score at month 1
and month 6. The validity/reliability of the 5-item reassur-
ance questionnaire in this population was assessed.
Secondary outcomes included the feasibility/accept-
ability of the discussion intervention, follow-up rates,
questionnaire completion rates, and patient-reported chest
pain, heart-related drug use, Hospital Anxiety and Depres-
sion Scale (HADS) [17], Brief Illness Perception Question-
naire (BIPQ) [18], Seattle Angina Questionnaire - UK
version (SAQ-UK) [19] with reference to chest pain/tight-
ness retained but reference to angina removed, Guys and
St Thomas’ chest pain questionnaire [20], EQ-5D [21] and
NHS resource use for chest pain (GP visits; inpatient, out-
patient and emergency hospital visits). Patients completed
questionnaires at baseline (collected by research nurse
prior to randomisation), at the end of the RACPC ap-
pointment (“post-clinic”; 5 reassurance questions only;
completed prior to leaving clinic), at month 1 and at month
6, and a 7-day chest pain diary at month 1 and month 6
(returned to YTU by post).Sample size
As a pilot trial, the main aim was to inform the feasibility
and sample size of a future multi-centre trial, however a
sample size calculation was carried out in order to obtain
reasonable estimates of effectiveness within the study.
Petrie et al. [12] observed a difference between the discus-
sion and pamphlet-alone arms with respect to the propor-
tion of patients reassured at one month (69% versus 40%
respectively). Assuming similar proportions for this study,
120 patients would be required to detect a difference with
80% power for a 2-sided, 5% significance level, allowing
for a 20% drop out rate.
Statistical methods
All analyses were conducted on an intention to treat basis,
including all patients in the arms to which they were
randomised, assuming data were available. No imputation
was carried out in this pilot analysis. Analyses were con-
ducted in SAS version 9.3 (SAS Institute, NC, USA).
The reliability and validity of the 5-item reassurance
questionnaire was investigated using standard psychomet-
ric tests. Internal consistency between items was tested
using Cronbach’s alpha, where >0.7 was considered accep-
table [22]. The distribution of individual items was sum-
marised in bar graphs to assess for skewness and floor or
ceiling effects. An assessment of test-retest reliability was
planned using the subset of patients with negative results
(NCCP diagnosis) at the end of their RACPC appointment
(post-clinic). We hypothesized that the post-clinic and
month 1 assessments would be stable for these patients.
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between CHD and NCCP patients and between patients
with low and high anxiety at baseline to see if the
questionnaire could distinguish between these groups
of patients where reassurance would be expected to be
different.
The proportion of patients reassured (defined as above
the median reassurance score, as per Petrie et al. [12])
was summarised by intervention arm and timepoint.
Since the categorisation using the median is fairly arbi-
trary we considered the continuous reassurance score as
primary. We also investigated whether the categorisation
above and below the median resulted in classifications as
reassured and not reassured broadly in line with how pa-
tients answered item 3 (How reassured were you by the
test?). Reassurance scores were compared between arms
using a repeated measures mixed model, accounting for
the baseline reassurance questions. No formal statistics
were planned or performed for any of the secondary out-
comes in this pilot study. Patient-reported outcomes
were summarised by intervention arm and timepoint.
The internal consistency of the overall BIPQ score was
tested using Cronbach’s alpha, where >0.7 was consid-
ered acceptable.
Health economic data
Patient-reported data on resource use (from the perspec-
tive of the NHS and Personal Social Services) and health
related quality of life (EQ5D) were summarised by inter-
vention arm and timepoint in order to preview future
cost-effectiveness analysis issues, such as the accuracy
and completeness of the data collection methods and
the need to account for censored/missing data in a fu-
ture trial.
Results
Primary outcomes
Recruitment and patient sample
120 patients (60/arm) were recruited in 8 months
(Oct 2011 to May 2012). Figure 1 shows the flow of
participants through the study and Table 2 summarises
their baseline characteristics. Around 40% of patients
attending RACPC were randomised in the study. All par-
ticipants received their allocated intervention: the pre-test
pamphlet plus a discussion with a nurse (Discussion arm)
or the pre-test pamphlet alone (Pamphlet arm). Patients
had a mean age of 54 (SD 12) and just under half were
male. Sixty-two (52%) patients were taking heart-related
medications at baseline, the majority of which were from
one or more of the following classes: beta blockers, statins,
anti-platelets, glyceryl trinitrate, other anti-anginals.
Forty-three (35.8%) patients received a diagnosis at
their initial clinic visit, whilst 65 (54.2%) returned for
further tests and got their diagnosis at a second visit.The remaining 12 (10.0%) patients were invited to return
for further tests but declined. Cardiac tests performed
are presented in Table 3. Final diagnoses are presented
in Table 4, with 76% of patients being diagnosed with
NCCP. Time to diagnosis from initial RACPC visit was a
median of 7 days (range 0 to 181 days), with 75% of pa-
tients receiving their diagnosis within two weeks of their
initial RACPC visit.
Reassurance questionnaire validity
Return rates for the reassurance questionnaire were
good, with 80% of participants returning a questionnaire
at month 1 and at month 6. However, the timing of
questionnaire return varied considerably, with month 1
questionnaires being completed at a median of 6 weeks
(range 4 to 17) and month 6 questionnaires at a median
of 28 weeks (range 24 to 41).
The validity of the reassurance questionnaire was inves-
tigated in this sample as previously it was used for NCCP
patients only [12]. Although there was some skewness, the
plots of responses to individual items did not show any
problems with floor or ceiling effects (see Additional file 2).
Internal consistency was borderline at the post-clinic
timepoint (Cronbach’s alpha = 0.68) and acceptable at
months 1 and 6 (0.82 and 0.78 respectively). Test-retest
reliability could not be established as, in practice, the time
between the post-clinic and planned month 1 question-
naire was too long to be considered a stable period (aver-
age 6 weeks). The subset of patients with questionnaires
within a two week window around month 1 showed sig-
nificant correlation between the two timepoints although
patient numbers were too small (n = 11) to conclude test-
retest reliability. Known group comparisons showed the
questionnaire could distinguish between clinically distinct
groups of patients, i.e. those with CHD versus NCCP and
those with high versus low anxiety.
Proportion reassured and reassurance score
Differences between the arms in the proportion of
patients classed as reassured were not consistent over
time (53% vs 48% at month 1 and 49% vs 58% at month 6
in the Discussion and Pamphlet arms respectively; Table 5).
Mean reassurance scores across the Discussion and
Pamphlet arms were similar at all timepoints; p = 0.08
using a repeated measures model (Figure 2). Question 3
(How reassured were you by the test?) indicated reason-
ably high reassurance immediately post-clinic and through
to month 6 in both arms (mean score 7 or 8 for each arm
at post-clinic, month 1 and month 6).
Secondary outcomes
Follow-up rates and questionnaire completion rates
There were no patient withdrawals or change of circum-
stances notified to the study site or YTU during the study.
Figure 1 Flow of participants through the study.
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(reassurance questionnaire; 79-99%). Other questionnaires
ranged from 28-100% completed (Table 6). Results pre-
sented as proportions of patients in the following sections
use these completion rates as the denominator unless
otherwise stated.
Patient-reported chest pain
At baseline 92/113 (81%) patients reported some chest
pain in the previous seven days. At month 1 a smaller
proportion of the Discussion arm reported chest pain in
the period since they last completed a questionnaire, 24/45
(53%) compared to 29/47 (62%) of the Pamphlet arm. At
month 6 these proportions were more similar (59% in the
Discussion arm vs 52% in the Pamphlet arm).
Data from a 7-day chest pain diary completed at month
1 and month 6 showed a similar reduction in the propor-
tion of patients reporting chest pain over time in both
arms (see table in Additional file 3).
Heart-related medications
52% of patients were taking heart-related medication at
baseline and the proportion reduced over time in botharms. A similar proportion in both arms reported taking
heart-related drugs at month 1 (43% in the Discussion
arm and 38% in the Pamphlet arm). At month 6 the pro-
portions were 40% of the Discussion arm and 29% of the
Pamphlet arm.
Other secondary outcomes
The discussion intervention, assessed through qualitative
interviews, was found to be acceptable to patients and
staff. This will be reported more fully elsewhere. Change
from baseline in treatment satisfaction from the SAQ-UK,
showed a trend towards improvement at month 1 for the
Discussion arm (median 8 points) with a return to base-
line levels by month 6, whilst the Pamphlet arm showed
no change at either timepoint. For other secondary out-
comes, the intervention arms showed similar trends over
time. Tables for secondary outcome data are available in
Additional file 4.
Health economic data
Completion rates for resource use questions and EQ5D are
summarised in Table 6. Health economic data will be pub-
lished separately (Moure Fernández et al., in preparation).
Table 3 Cardiac tests performed by intervention arm
Discussion
(n = 60)
Pamphlet
(n = 60)
Total
(n = 120)
Exercise tolerance test (ETT) 29 38 67
Dobutamine stress
echocardiogram (DSE)
28 24 52
Exercise echocardiogram 5 8 13
Echocardiogram 1 0 1
Myocardial perfusion scan (MPS) 0 0 0
Magnetic resonance imaging (MRI) 0 0 0
Table 4 Test results by intervention arm
Diagnosis Allocation All
Discussion Pamphlet
N % N % N %
CHD 10 16.7 7 11.7 17 14.2
- Referred for angiogram 3 4
- Medication with review at 3 months 7 3
NCCP 46 76.7 45 75.0 91 75.8
Inconclusive 4 6.7 8 13.3 12 10.0
CHD coronary heart disease, NCCP non-cardiac chest pain.
Table 2 Baseline characteristics of the study population
Patients N (%) Allocation
Discussion (n = 60) Pamphlet (n = 60)
Male:Female 29 (48%): 31 (52%) 30 (50%): 30 (50%)
Mean age (years) (SD) 55 (12.3) 53 (12.0)
Ethnicity:
White 52 (87%) 51 (85%)
Mixed 2 (3%) 1 (2%)
Asian or Asian British 5 (8%) 7 (12%)
Black or Black British 1 (2%) 0 (0%)
Other 0 (0%) 1 (2%)
Education beyond
minimum school
leaving age
33 (55%) 41 (68%)
Degree or equivalent
qualification
23 (38%) 27 (45%)
Employment:
Employed/Self-employed 32 (53%) 35 (58%)
Retired 12 (20%) 13 (22%)
Other 13 (22%) 12 (20%)
Marital Status:
Single 8 (13%) 14 (23%)
Married/permanent
partnership
41 (68%) 33 (55%)
Divorced 4 (7%) 9 (15%)
Widowed 7 (12%) 4 (7%)
Number of weeks with
chest pain (median, range)
6 (1–500) 6 (1–200)
Number of times in
last 7 days had chest
pain (median, range)
3 (0–14) 2 (0–21)
Taking heart-related*
medications at baseline
30 (50%) 32 (53%)
High risk for CHD 32 (53%) 34 (57%)
*Heart-related medications included beta blockers, statins, anti-platelets, glyceryl
trinitrate and other anti-anginals.
SD standard deviation, CHD coronary heart disease.
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An aim of the pilot was to provide information regarding
the feasibility of conducting a large-scale trial in this
patient population. Prior to the pilot, during the develop-
ment of the interventions, patients received information
about the study by letter and were asked to telephone a
YTU researcher if they were interested in taking part. The
response rate for this strategy was very poor and so it was
altered for the pilot RCT. Rather than having actively to
telephone a researcher, patients were asked by clinic staff
on arrival at RACPC if they wanted to take part. This was
much more successful, with an uptake rate for patients
attending RACPC to recruitment into the pilot trial at
around 40%.
We considered that the discussion intervention could
improve reassurance in all patients attending RACPC, so
patients with both positive (CHD) and negative (NCCP)
test results were included in this pilot. Consistent with
other studies, the majority of the patients recruited in
RACPC received an NCCP diagnosis. Only 14% of pa-
tients were diagnosed with CHD so our numbers were too
small to investigate effectiveness in the CHD subgroup
separately. For example, we wished to investigate how
satisfied patients receiving a CHD diagnosis were with
their proposed treatment, measured by the treatment
satisfaction scale within SAQ-UK, however this was not
possible due to low numbers. Future trials would have to
be considerably larger to recruit a reasonable number of
CHD patients from this setting.
Return rates for the reassurance questionnaire were rea-
sonable (80%) but many participants required one or more
reminders. Up to three reminders were sent: reminder
letters after 3 and 4 weeks with a final telephone reminder
after 4 to 5 weeks. This led to some questionnaires being
completed much later than planned. An earlier telephone
reminder to encourage the return of primary outcome
data should be considered for future trials. However, we
do not think this altered our main outcomes following a
sensitivity analysis including all patients with a question-
naire returned within a two week window either side of
month 1.
Table 5 - Proportion of patients reassured at post-clinic, month 1 and month 6
% (95% confidence interval) Post-clinic (n = 117) Month 1 (n = 95) Month 6 (n = 95)
Discussion 50.9 (38.1 to 63.6) 53.2 (38.9 to 67.5) 48.9 (34.3 to 63.5)
Pamphlet 58.6 (46.9 to 71.3) 47.9 (33.8 to 62.1) 58.0 (44.3 to 71.7)
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naires were lower (Guys and St Thomas’, HADS, BIPQ,
SAQ-UK, chest pain questions and diaries). This was
partly because patients’ responses to the reassurance
questionnaire were collected during the reminder tele-
phone call, but not the other questionnaires. Also, it is
possible that the other questionnaires seemed less relevant
to patients at month 1 and month 6, particularly if they
were no longer experiencing chest pain. For example the
BIPQ refers to the patient’s “illness”, whilst SAQ-UK and
Guys and St Thomas’ questionnaire refer to chest pain or
tightness. For future studies in this area, only the most
relevant questionnaires should be included, focussing
on those with high compliance. Additional instructions
within the questionnaire could be included to improve
completion rates.
This pilot study included investigations into the effective-
ness of the discussion intervention, in terms of providing
reassurance to patients about their test results in RACPC.
According to a recent review “there is no generally accep-
ted instrument to measure the level of reassurance” [23].
We used the 5-item instrument used in the NZ study. The
questionnaire had not previously been validated in CHDFigure 2 Reassurance score over time. Score ranges from 0 to 50 with hi
by a line and the mean by 'O' or ' + '. The shaded box represents the interquapatients, but we found it to be reliable and valid in our
study population. In order to investigate whether Petrie’s
categorisation of reassured/not reassured seemed appro-
priate, we looked at how patients answered question 3
(How reassured were you by the test? 0 represents ‘not
at all’ and 10 represents ‘extremely reassured’; Additional
file 5). A number of patients classed as ‘not reassured’ had
high scores on this question (34 patients with score ≥ 8). A
few patients answered 0 or 1 but are categorised as ‘reas-
sured’. If the reassurance questionnaire was to be used in
a future study, further investigation into how to classify
patients into ‘reassured’ and ‘not reassured’ would be
recommended.
We found no evidence of a difference in reassurance
(both proportion of patients classed as “reassured” or
mean score) between the discussion and pamphlet-only
arms at month 1 or 6. The NZ study reported a signifi-
cantly higher proportion of reassured patients in the dis-
cussion group (69%) compared to both the pamphlet-only
group (40%) and a usual care control (35%) at month 1.
Their results using mean reassurance score, however, were
more similar to our pilot study; at month 1 the mean
score was higher in the discussion group (43.4; 95% CI:gher scores representing more reassurance. The median is represented
rtile range. Outliers are identified using 'o'.
Table 6 Questionnaire completion rates
Number (%) completed (of 120 randomised) Baseline Post-clinic Month 1 Month 6
Reassurance questionnaire 119 (99%) 117 (98%) 95 (79%) 95 (79%)
Chest pain questions 113 (94%) NA 92 (77%) 92 (77%)
Chest pain diaries NA NA 88 (73%) 74 (62%)
Heart-related medications 120 (100%)* NA 97 (81%) 98 (82%)
BIPQ (overall score) 98 (82%) NA 72 (60%) 61 (51%)
SAQ-UK 119 (99%) NA 92 (77%) 80 (67%)
HADS 117 (98%) NA 92 (77%) 83 (69%)
Guys and St Thomas 91 (76%) NA 56 (47%) 33 (28%)
EQ5D 115 (96%) NA 90 (75%) 82 (68%)
NHS resource use NA NA 91 (76%) 83 (69%)
NA = Not applicable at this timepoint.
*Collected by clinic staff at initial RACPC visit; all other questionnaires were patient-reported.
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http://www.biomedcentral.com/1471-2261/14/13841.0 – 45.8) compared to both the pamphlet-only (38.4;
95% CI: 35.4 – 41.4) and control group (34.4; 95% CI:
30.5 – 38.4), but only the difference between discussion
and control groups reached statistical significance. The
NZ study was just in patients who received a negative
(NCCP) test result, whereas this UK pilot also included
patients diagnosed with CHD. Our sensitivity analyses
on the NCCP subgroup showed a possible trend for
higher reassurance in the Discussion arm (Additional
file 6) but these differences were smaller than seen in the
NZ study and not sustained at 6 months, and not consid-
ered to be clinically relevant.
The clinic setting for the studies was different, and it
was likely that the experience for the patients in clinic
was different. The UK pilot was conducted in a tertiary
cardiology centre, with patients receiving more than one
test (compared to just an ETT in the NZ study) and
interaction with different staff for the different tests. It is
possible that the usual care advice/information and
explanation of test results in the UK RACPC was of a
standard such that no additional benefit could be gained
from a pre-test discussion. The discussion intervention
was delivered by a research nurse who was not trained in
psychological techniques and this may have contributed
to the ineffectiveness of the discussion intervention. The
target is to see UK patients in RACPC within 2 weeks of
their GP visit, although this was not measured in this
study, whereas patients had to wait longer for their clinic
appointment in the NZ study (median 6 weeks). The NZ
patients had more time to build up negative beliefs, which
can influence reassurance in people with NCCP [13].
A limitation to this pilot was the absence of a third
“no pre-test information” control arm. This was because
Greater Manchester, where the study was conducted,
had recommended that a Petrie-style pre-test pamphlet
should be usual care in RACPC. As a result, we have noinformation on whether a pre-test pamphlet alone is
better than no pre-test information in a UK setting.
Since RACPCs are likely to send an information pamph-
let with the appointment letter anyway, for example
explaining what clothes to wear and what tests the pa-
tients may have in RACPC, it may be that RACPCs in
regions other than Greater Manchester should consider
including information regarding possible test results and
ensuing treatments.
Conclusions
An additional face-to-face discussion with a nurse, which
re-iterated information given in a pre-test pamphlet, did
not significantly improve reassurance in patients. Whilst
there was a possible trend in the NCCP subgroup for
improved reassurance with a discussion, the difference
was not considered to be clinically important and does
not warrant a larger trial of the discussion intervention
in UK RACPCs.
Additional files
Additional file 1: Pretest pamphlet. All patients in the study received
this pre-test pamphlet (A5, 4 pages) at the start of their RACPC
appointment.
Additional file 2: Responses to 5 reassurance questions.doc.
Plots of patients’ responses to the five questions (Questions 1 to 5) in the
reassurance questionnaire at baseline (Questions 1 and 2 only), post-clinic,
month 1 and month 6. Answers on a 0–10 scale.
Additional file 3: Chest pain diary data. Table presenting patient-
reported chest pain in a 7-day period at month 1 and month 6, collected
from chest pain diaries.
Additional file 4: Secondary outcome data_HADS_BIPQ_SAQ-UK_Guys
and St Thomas. Three tables: (i) Change from baseline, at month 1 and
month 6, for HADS, BIPQ and SAQ-UK; (ii) Individual item scores from the
Brief Illness Perception Questionnaire at baseline, month 1 and month 6
and (iii) Guys and St Thomas’ chest pain score at baseline, month 1 and
month 6.
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http://www.biomedcentral.com/1471-2261/14/138Additional file 5: Reassurance Question 3. Patients’ response to
Question 3 of the Reassurance Questionnaire (How reassured were you
by the test?) for those categorised as “reassured” and “not reassured”
according to the method of Petrie et al., 2007.
Additional file 6: NCCP subgroup results. Proportion of patients
reassured and reassurance score at month 1 and month 6 for NCCP
patients only.
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